Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 531 to 540 of 2591 total matches.

Tramadol Oral Solution (Qdolo) for Pain

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
opioid agonist and a weak serotonin and norepinephrine reuptake inhibitor.1 It is metabolized by CYP2D6 ...
The opioid agonist tramadol is now available in an oral solution (Qdolo – Athena Bioscience) for management of pain severe enough to require an opioid and for which alternative treatment options are inadequate. Tramadol has been available for years in immediate-release tablets and capsules, extended-release capsules (Ultram, and others), and in a fixed-dose combination tablet with acetaminophen (Ultracet, and generics).
Med Lett Drugs Ther. 2021 May 31;63(1625):83-4 |  Show IntroductionHide Introduction

Inhaled Mannitol (Bronchitol) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
of bronchial hyperresponsiveness. Table 1. Pharmacology Formulation 40 mg dry powder capsules Route ...
The FDA has approved mannitol powder for oral inhalation (Bronchitol – Chiesi) as add-on maintenance treatment to improve pulmonary function in adults with cystic fibrosis (CF). This product has been available in Europe for the same indication since 2012. Another formulation of mannitol inhalation powder (Aridol) is approved in the US for assessment of bronchial hyperresponsiveness.
Med Lett Drugs Ther. 2021 May 31;63(1625):85-6 |  Show IntroductionHide Introduction

Teprotumumab (Tepezza) for Thyroid Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2021 May 31;63(1625):87-8 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
-19 vaccine to include adolescents 12-15 years old.1 The vaccine has been authorized for use ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 |  Show IntroductionHide Introduction

Plenity for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
with a BMI ≥25 kg/m2 for years.1 THE DEVICE — Taken with water before lunch and dinner, Plenity capsules ...
Plenity (Gelesis), a nonsystemic oral superabsorbent hydrogel formulation of cellulose and citric acid is now available. It was cleared by the FDA in 2019 to aid in weight management together with diet and exercise in overweight and obese adults (BMI of 25-40 kg/m2). It is classified by the FDA as a device because the contents of the capsule are not absorbed systemically. Plenity is the first ingested, transient, space-occupying hydrogel to be marketed in the US and the only weight management treatment available by prescription for patients with a BMI of 25-30 kg/m2, regardless of...
Med Lett Drugs Ther. 2021 May 17;63(1624):77-8 |  Show IntroductionHide Introduction

Antibacterial Drugs for Lyme Disease

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
is also transmitted by I. scapularis, has been shown to cause a similar illness in the upper Midwest.1-3 ...
Lyme disease in the US is caused by the spirochete Borrelia burgdorferi, which is transmitted to humans by Ixodes scapularis (blacklegged [deer] tick) and I. pacificus (western blacklegged tick). Most cases of Lyme disease occur in late spring and early summer in northeastern and mid-Atlantic states, the upper Midwest, and in northern California. B. mayonii, which is also transmitted by I. scapularis, has been shown to cause a similar illness in the upper Midwest.
Med Lett Drugs Ther. 2021 May 17;63(1624):73-5 |  Show IntroductionHide Introduction

Loteprednol 0.25% (Eysuvis) for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
inhibitors (SSRIs). Dry eye disease is most prevalent in women and older adults.1,2 STANDARD TREATMENT ...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for short-term treatment (≤2 weeks) of dry eye disease. It is the first ocular corticosteroid to be approved for this indication. Other formulations of loteprednol are approved for treatment of steroid-responsive ocular inflammatory conditions, inflammation after ocular surgery, and seasonal allergic conjunctivitis.
Med Lett Drugs Ther. 2021 May 17;63(1624):75-7 |  Show IntroductionHide Introduction

MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
impairment. Rates of meningococcal disease are highest in infants ...
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y (MenACWY) in persons ≥2 years old.
Med Lett Drugs Ther. 2021 May 17;63(1624):78-80 |  Show IntroductionHide Introduction

In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
million doses of the single-dose vaccine had been administered in the US at the time of the review.1-4 ...
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the...
Med Lett Drugs Ther. 2021 May 17;63(1624):e1 |  Show IntroductionHide Introduction

Vibegron (Gemtesa) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
to be approved in the US; mirabegron (Myrbetriq) was the first.1 STANDARD TREATMENT — Overactive bladder (OAB ...
The FDA has approved the selective beta-3 adrenergic agonist vibegron (Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (Myrbetriq) was the first.
Med Lett Drugs Ther. 2021 May 3;63(1623):67-9 |  Show IntroductionHide Introduction